RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

NCT02489903 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

139

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Carcinoma
Carcinoma, Non-Small-Cell Lung
Neuroendocrine Tumors
Ovarian Epithelial Cancer

Interventions

DRUG: RRx-001
DRUG: Cisplatin
DRUG: Etoposide
DRUG: Carboplatin
DRUG: Irinotecan
DRUG: Vinorelbine
DRUG: Doxil
DRUG: Gemcitabine
DRUG: Taxane
DRUG: Paclitaxel
DRUG: Nab-Paclitaxel
DRUG: Pemetrexed

Sponsor

EpicentRx, Inc.